High doses of vitamin E in the treatment of disorders of the central nervous system in the aged

American Journal of Clinical Nutrition

Volumn 70, Issue 5, 1999, Pages 793-801

  Vatassery, Govind T ^a   Bauer, Timothy ^b   Dysken, Maurice ^b  

^a VA MEDICAL CENTER   (United States)

^b NONE

Author keywords

Aged; Alzheimer disease; Antioxidants; Cardiovascular disease; Central nervous system; Elderly; Megadose; Parkinson disease; Tardive dyskinesia; Therapeutic agent; Vitamin E; tocopherol

Indexed keywords

ALPHA TOCOPHEROL;

AGED; ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR DISEASE; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG RESEARCH; DRUG SAFETY; GERIATRIC PATIENT; HUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; REVIEW; TARDIVE DYSKINESIA;

EID: 0032744787     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn/70.5.793     Document Type: Review

References (86)

1. Burton GW, Joyce A, Ingold KU. Is vitamin E the only lipid-soluble, chain-breaking antioxidant in human blood plasma and erythrocyte membranes? Arch Biochem Biophys 1983;221:281-90.
2. Ingold KU, Webb AC, Witter D, Burton GW, Metcalfe TA, Muller DPR. Vitamin E remains the major lipid-soluble, chain-breaking antioxidant in human plasma even in individuals suffering severe vitamin E deficiency. Arch Biochem Biophys 1987;259:224-5.
3. Vatassery GT. Vitamin E: neurochemistry and implications for Parkinson's disease. Ann NY Acad Sci 1992;669:97-110.
4. Horwitt MK. The promotion of vitamin E. J Nutr 1986;116:1371-7.
5. Weber P, Bendich A, Machlin LJ. Vitamin E and human health: rationale for determining recommended intake levels. Nutrition 1997;13:450-60.
6. Burton GW, Traber MG, Acuff RV, et al. Human plasma and tissue α-tocopherol concentrations in response to supplementation with deuterated natural and synthetic vitamin E. Am J Clin Nutr 1998;67: 669-84.
7. Weiser H, Riss G, Korman AW. Biodiscrimination of the eight alpha tocopherol stereoisomers results in preferential accumulation of the four 2R forms in tissues and plasma of rats. J Nutr 1996;126:2539-49.
8. Machlin LJ. Vitamin E. In: Machlin LJ, ed. Handbook of vitamins. New York: Marcel Dekker, 1990:99-145.
9. National Research Council. Recommended dietary allowances. Washington, DC: National Academy Press, 1989:99-107.
10. Cohn W. Bioavailability of vitamin E. Eur J Clin Nutr 1997; 51(suppl):S80-5.
11. Clement M, Bourre JM. Graded dietary levels of RRR gamma tocopherol induce a marked increase in the concentrations of alpha and gamma tocopherol in nervous tissues, heart, liver and muscle of vitamin E-deficient rats. Biochim Biophys Acta 1997;1334:173-81.
12. Machlin LJ. Use and safety of elevated dosages of vitamin E in adults. Int J Vitam Nutr Res 1989;30(suppl):56-68.
13. Nutrition labeling of foods. Code of federal regulations. Washington, DC: US Government Printing Office, 1998:20-49.
14. Garry PJ, Hunt WC. Biochemical assessment of vitamin status in the elderly: effects of dietary and supplemental intakes. In: Hutchinson ML, Munro HN, ed. Nutrition and aging. New York: Academic Press, 1986:117-37.
15. Tanyel MCM, Mancano LD. Neurologic findings in vitamin E deficiency. Am Fam Physician 1997;55:197-201.
16. Vatassery GT, Brin MF, Fahn S, Kayden HJ, Traber MG. Effect of high doses of dietary vitamin E on the concentrations of vitamin E in several brain regions, plasma, liver and adipose tissue of rats. J Neurochem 1988;51:621-3.
17. Sokol RJ. Vitamin E and neurologic deficits. Adv Pediatr 1990; 37:119-48.
18. Muller DPR, Lloyd JK, Wolff OH. Vitamin E and neurological function. Lancet 1983;1:225-8.
19. Traber MG, Sokol RJ, Burton GW, et al. Impaired ability of patients with familial isolated vitamin E deficiency to incorporate alpha tocopherol into lipoproteins secreted by the liver. J Clin Invest 1990;85:397-407.
20. Catignani GL, Bieri JG. Rat liver alpha tocopherol binding protein. Biochim Biophys Acta 1977;497:349-57.
21. Ouahchi K, Arita M, Kayden HJ, et al. Ataxia with isolated vitamin E deficiency is caused by mutations in the alpha tocopherol transfer protein. Nat Genet 1995;9:141-5.
22. Cavalier L, Ouahchi K, Kayden HJ, et al. Ataxia with isolated vitamin E deficiency: heterogeneity of mutations and phenotypic variability in a large number of families. Am J Hum Genet 1998;62:301-10.
23. Traber MG. Regulation of human plasma vitamin E. Adv Pharmacol 1997;38:49-63.
24. Fahn S, Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol 1992;32:804-12.
25. Ebadi M, Srinivasan SK, Baxi MD. Oxidative stress and antioxidant therapy in Parkinson's disease. Prog Neurobiol 1996;48:1-19.
26. de Rijk MC, Breteler MMB, den Breeijen JH, et al. Dietary antioxidants and Parkinson's disease. Arch Neurol 1997;54:762-5.
27. Golbe LI, Farrell TM, Davis PH. Case-control study of early life dietary factors in Parkinson's disease. Arch Neurol 1988;45:1350-3.
28. Logroscino G, Marder K, Cote L, Tang MX, Shea S, Mayeux R. Dietary lipids and antioxidants in Parkinson's disease: a population-based case control study. Ann Neurol 1996;39:89-94.
29. Cohen G. The pathobiology of Parkinson's disease: biochemical aspects of dopamine neuron senescence. J Neural Transm Suppl 1983; 19:89-103.
30. The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328:176-83.
31. Shoulson I, The Parkinson Study Group. DATATOP: a decade of neuroprotective inquiry. Ann Neurol 1998;44(suppl):S160-6.
32. Bernheimer H, Birkmayer W, Hornykiewicz O. Brain dopamine and the syndromes of Parkinson and Huntington. J Neurol Sci 1973;20:415-55.
33. Vatassery GT, Fahn S, Kuskowski MA, The Parkinson Study Group. Alpha tocopherol in CSF of subjects taking high-dose vitamin E in the DATATOP study. Neurology 1998;50:1900-2.
34. Fahn S. A pilot trial of high dose alpha tocopherol and ascorbate in early Parkinson's disease. Arch Neurol 1992;32:S128-32.
35. The Parkinson Study Group. DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Arch Neurol 1989;46:1052-60.
36. Markesbery WR. Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med 1997;23:134-47.
37. Multhaup G, Ruppert T, Schlicksupp A, et al. Reactive oxygen species and Alzheimer's disease. Biochem Pharmacol 1997;54:533-9.
38. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of seligiline, alpha tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med 1997;336:1216-22.
39. Drachman DA, Leber P. Treatment of Alzheimer's disease: searching for a breakthrough, settling for less. N Engl J Med 1997;336:1245-7.
40. Landau WM. Clinical neuromythology IX. Pyramid sale in the bucket shop: DATATOP bottoms out. Neurology 1990;40:1337-9.
41. The Parkinson Study Group. DATATOP and clinical neuromythology IX. Neurology 1991;41:771-3.
42. Sano M, Thomas RG, Thal LJ. Alpha tocopherol and Alzheimer's disease: the authors reply. N Engl J Med 1997;337:572-3 (letter).
43. Steinberg D. Oxidative modification of LDL and atherogenesis. Circulation 1997;95:1062-71.
44. Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 1993;328:1450-6.
45. Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC. Vitamin E consumption and coronary heart disease in women. N Engl J Med 1993;328:1444-9.
46. Jha P, Flather M, Lonn E, Farkouh M, Yusuf S. The antioxidant vitamins and cardiovascular disease: a critical review of epidemiological and clinical trial data. Ann Intern Med 1995;123:860-72.
47. Stephens NG, Parsons A, Schofield PM, et al. Randomized controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996;347:781-6.
48. Steiner M. Vitamin E: more than an antioxidant. Clin Cardiol 1993; 16(suppl):116-8.
49. Diaz MN, Frei B, Vita JA, Keaney JF Jr. Antioxidants and atherosclerotic heart disease. N Engl J Med 1997;337:408-16.
50. Azzi A, Boscoboinik D, Clement S, et al. Alpha tocopherol as a modulator of smooth muscle cell proliferation. Prostaglandins Leukot Essent Fatty Acids 1997;57:507-14.
51. Chan AC. Vitamin E and atherosclerosis. J Nutr 1998;128:1593-6.
52. Schroeder DJ, Hart LL, Miyagi SL. Vitamin E in tardive dyskinesia. Ann Pharmacother 1993;27:311-3.
53. Cadet JL, Kahler LA. Free radical mechanisms in schizophrenia and tardive dyskinesia. Neurosci Biobehav Rev 1994;18:457-67.
54. Cadet JL, Lohr JB, Jeste DV. Free radicals and tardive dyskinesia. Trends Neurosci 1986;9:107-8.
55. Lohr JB, Caligiuri MP. A double-blind placebo controlled study of vitamin E treatment of tardive dyskinesia. J Clin Psychiatry 1996; 57:167-73.
56. Adler LA, Edson R, Lavori P, et al. Long term treatment effects of vitamin E for tardive dyskinesia. Biol Psychiatry 1998;43:868-72.
57. Lohr JB, Lavori P. Whither vitamin E and tardive dyskinesia? Biol Psychiatry 1998;43:861-2 (editorial).
58. Bendich A, Machlin LJ. Safety of oral intake of vitamin E. Am J Clin Nutr 1988;48:612-9.
59. Meydani SN, Meydani M, Blumberg JB, et al. Assessment of the safety of supplementation with different amounts of vitamin E in healthy older adults. Am J Clin Nutr 1998;68:311-8.
60. Diplock AT. Safety of antioxidant vitamins and β-carotene. Am J Clin Nutr 1995;62(suppl):1510S-6S.
61. The Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Ann Neurol 1996;39:37-45.
62. Nelson L. The effect of intravenous vitamin E and menadiol sodium diphosphate on vitamin K dependent clotting factors. Thromb Res 1984; 35:11-8.
63. Corrigan JJ Jr. The effect of vitamin E on warfarin-induced vitamin K deficiency. Ann N Y Acad Sci 1982;393:361-8.
64. Dowd P, Zheng ZB. On the mechanism of the anticlotting action of vitamin E quinone. Proc Natl Acad Sci U S A 1995;92:8171-5.
65. Berson EL, Rosner B, Sandberg MA, et al. A randomized trial of vitamin A and vitamin E supplementation for retinitis pigmentosa. Arch Ophthalmol 1993;111:761-72.
66. Olson JA. Vitamin A, retinoids and carotenoids. In: Shils ME, Olson JA, Shike M, ed. Modern nutrition in health and disease. Vol 1, 8th ed. Philadelphia: Lea & Febiger, 1994:287-307.
67. Massof RW, Finkelstein D. Supplemental vitamin A retards loss of ERG amplitude in retinitis pigmentosa. Arch Ophthalmol 1993;111:751-4.
68. Yokota T, Shiojiri T, Gotoda T, et al. Friedrich-like ataxia with retinitis pigmentosa caused by the His101Gln mutation of the alpha-tocopherol transfer protein. Ann Neurol 1997;41:826-32.
69. Robinson WG Jr, Kuwabara T, Bieri JG. Vitamin E deficiency and the retina: photoreceptor and pigment epithelial changes. Invest Ophthalmol Vis Sci 1979;18:683-90.
70. Scott ML. Studies on vitamin E and related factors in nutrition and metabolism. In: DeLuca HF, Suttie JW, ed. The fat soluble vitamins. Madison, WI: The University of Wisconsin Press, 1969:355-68.
71. Vatassery GT, Angerhofer CK, Peterson FJ. Vitamin E concentrations in the brains and some selected peripheral tissues of selenium-deficient and vitamin E-deficient mice. J Neurochem 1984;42:554-8.
72. Nelson JS. Pathology of vitamin E deficiency. In: Machlin LJ, ed. Vitamin E: a comprehensive treatise. New York: Marcel Dekker, 1980: 391-428.
73. Schmidt RE, Coleman BD, Nelson JS. Differential effect of chronic vitamin E deficiency on the development of neuroaxonal dystrophy in rat gracile/cuneate nuclei and prevertebral sympathetic ganglia. Neurosci Lett 1991;123:102-6.
74. Muller DPR. Vitamin E and neurological function: lessons from patients with abetalipoproteinemia. Redox Rep 1995;1:239-45.
75. Muller DPR, Goss-Sampson MA. Neurochemical, neurophysiological, and neuropathological studies in vitamin E deficiency. Crit Rev Neurobiol 1990;5:239-63.
76. Xie Z, Sastry BR. Impairment of long-term potentiation in rats fed with vitamin E-deficient diet. Brain Res 1995;681:193-6.
77. Bertoni-Freddari C, Giuli C, Pieri C. Effect of chronic vitamin E deficiency on the synapses of cerebellar glomeruli in young rats. Mech Ageing Dev 1984;24:225-32.
78. Desjardins GC, Beaudet A, Schipper HM, Brawer JR. Vitamin E protects hypothalamic beta-endorphin neurons from estradiol neurotoxicity. Endocrinology 1992;131:2482-4.
79. 2 in brain regions of young and old rats. Prostaglandins Leukot Med 1985;18:337-46.
80. 2 in liver and brains of chicks posthatching: the influence of dietary fat and vitamin E. Ann Nutr Metab 1995;39:302-9.
81. Azzi A, Boscoboinik D, Marilley D, Özer NK, Stäuble B, Tasinato A. Vitamin E: a sensor and information transducer of the cell oxidation state. Am J Clin Nutr 1995;62(suppl):1337S-46S.
82. Ricciarelli R, Tasinatto A, Clement S, Özer NK, Boscoboinik D, Azzi A. Alpha tocopherol specifically inactivates cellular protein kinase C alpha by changing its phosphorylation site. Biochem J 1998;334: 243-9.
83. Kappus H, Diplock AT. Tolerance and safety of vitamin E: a toxicological position report. Free Radic Biol Med 1992;13:55-74.
84. Steinberg D. Clinical trials of antioxidants in atherosclerosis: are we doing the right thing? Lancet 1995;346:36-8.
85. Angell M, Kassirer JP. Clinical research: what should the public believe? N Engl J Med 1994;331:189-90.
86. Block G. Are clinical trials really the answer? Am J Clin Nutr 1995; 62(suppl):1517S-20S.